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SUMMARY
A20 is a potent anti-inflammatory protein that inhibits NF-κB, and A20 dysfunction is associated
with autoimmunity and B-cell lymphoma. A20 harbors a deubiquitination enzyme domain and can
employ multiple mechanisms to antagonize ubiquitination upstream of NEMO, a regulatory
subunit of the IκB kinase complex (IKK). However, direct evidence of IKK inhibition by A20 is
lacking, and the inhibitory mechanism remains poorly understood. Here we show that A20 can
directly impair IKK activation without deubiquitination or impairment of ubiquitination enzymes.
We find that polyubiquitin binding by A20, which is largely dependent on A20’s seventh zinc
finger motif (ZnF7), induces specific binding to NEMO. Remarkably, this ubiquitin-induced
recruitment of A20 to NEMO is sufficient to block IKK phosphorylation by its upstream kinase
TAK1. Our results suggest a non-catalytic mechanism of IKK inhibition by A20 and a means by
which polyubiquitin chains can specify a signaling outcome.
INTRODUCTION
NF-κB, a dimeric transcription factor consisting of the Rel family of proteins, controls genes
involved in inflammation, immunity, and cell survival (Hayden and Ghosh, 2008). Under
basal conditions, NF-κB is sequestered in the cytoplasm by inhibitor of NF-κB (IκB).
Stimulation of cells with any of a multitude of agents, including inflammatory cytokines and
toll-like receptor (TLR) ligands, induces IκB phosphorylation by the IκB kinase (IKK).
Phosphorylated IκB is ubiquitinated, then degraded by the proteasome, liberating NF-κB to
enter the nucleus and regulate gene expression.
Best known for its role in targeting protein degradation by the proteasome, ubiquitin also has
non-degradative functions, including regulation of IKK (Chen and Sun, 2009). Indeed,
binding of the TNF receptor (TNFR), IL-1 receptor (IL-1R), and many TLRs to their
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respective ligands results in activation of ubiquitin ligases. In the IL-1R and many TLR
pathways, TNF receptor-associated factor 6 (TRAF6) is the major ubiquitin ligase. TRAF6
works with the dimeric ubiquitin-conjugating enzyme UBC13/UEV1A to synthesize
polyubiquitin chains linked through Lys 63 (K63) of ubiquitin (Deng et al., 2000). Indeed,
the E3 ligase activity of TRAF6, the catalytic activity of UBC13, and K63 of ubiquitin are
required for IL-1β-induced IKK activation (Lamothe et al., 2008; Xu et al., 2009). In the
TNFR pathway, numerous ubiquitin ligases are recruited, including TRAF2, cellular inibitor
of apoptosis (cIAP) 1 and 2, and linear ubiquitin chain assembly complex (LUBAC)
(Bianchi and Meier, 2009; Haas et al., 2009). The linkage of polyubiquitin chains in this
pathway remains enigmatic, and it is unclear why so many ubiquitin ligases, and potentially
different polyubiquitin linkages, are involved. Nevertheless, polyubiquitin chains clearly
play an essential role in TNFα-induced IKK activation. In the TNFR pathway, receptor-
interacting protein kinase 1 (RIP1) is a key ubiquitination substrate (Ea et al., 2006; Wu et
al., 2006). In the IL-1R/TLR4 pathway, several proteins, including IL-1R associated kinase
1 (IRAK1) and TRAF6, are known to be ubiquitinated, but only unanchored polyubiquitin
chains have been shown to directly activate TAK1 and IKK (Xia et al., 2009). The
polyubiquitin chains in each pathway bind to the regulatory subunits of the TGFβ-activated
kinase (TAK1) and IKK complexes, TAB2 and NEMO, respectively, and this binding leads
to TAK1 and IKK activation (Ea et al., 2006; Kanayama et al., 2004; Laplantine et al., 2009;
Wu et al., 2006). Activated TAK1 phosphorylates IKK, as well as MAP kinase kinases such
as MKK6, promoting activation of IKK and MAP kinase signaling pathways (Wang et al.,
2001).
A20 is a potent suppressor of the NF-κB signaling pathways, and A20 deficiency in mice
results in excessive NF-κB activity and multiorgan inflammation (Boone et al., 2004; Lee et
al., 2000). Recent evidence also implicates dysfunction of A20 as a risk factor for human
disease. Polymorphisms in the A20 locus are associated with multiple autoimmune diseases
including systemic lupus erythematosis, and A20 was recently identified as a tumor
suppressor in B-cell lymphoma (Compagno et al., 2009; Kato et al., 2009; Musone et al.,
2008; Schmitz et al., 2009; Vereecke et al., 2009). A20 has an N-terminal ovarian tumor
(OTU) domain and seven C-terminal zinc finger (ZnF) motifs. The OTU domain can
deubiquitinate RIP1, and the ZnF region can act as an E3 ligase to add K48 polyubiquitin
chains to RIP1, promoting its proteasomal degradation (Wertz et al., 2004). A20 also
promotes disassembly of ubiquitination complexes in the IL-1R and TNFR pathways,
including TRAF6-UBC13; cIAP1/2-UBC13; and cIAP1/2-UBCH5, as well as proteasomal
degradation of UBC13 and UBCH5 (Shembade et al., 2010). Both deubiquitination and
disassembly of E2-E3 complexes require A20’s catalytic Cys 103 residue within the OTU
domain. A20 has also been reported to block recruitment of the adaptor proteins TRADD
and RIP1 to TNFR (He and Ting, 2002), and to promote lysosomal degradation of TRAF2
(Li et al., 2009). Although the relative contributions of deubiquitination, degradation of
upstream signaling proteins, and disruption of ubiquitination complexes remain unclear,
A20 appears to employ multiple mechanisms that could potentially reduce the amount of
polyubiquitin chains available to interact with TAB2 and NEMO.
Yet certain data are difficult to reconcile with the proposed catalytic mechanisms. For
example, in vitro, A20’s OTU domain readily disassembles K48 polyubiquitin chains, but
only weakly disassembles K63 polyubiquitin chains (Komander and Barford, 2008; Lin et
al., 2008). In addition, overexpression of A20 mutants lacking the catalytic Cys 103 residue
inhibits NF-κB, suggesting a non-catalytic mechanism (Evans et al., 2004; Song et al.,
1996). Furthermore, there is no direct evidence that A20 reduces the amount of
polyubiquitin chains available to interact with TAB2 and NEMO.
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We found evidence that A20 can inhibit IKK through a mechanism that cannot be accounted
for by reducing the interaction of polyubiquitin chains with NEMO. We found that
polyubiquitin binding, which is largely dependent on ZnF7, is required for IKK inhibition.
Polyubiquitin chains non-covalently recruit A20 to NEMO, forming a complex involving
specific NEMO-A20 interaction. Remarkably, when bound to the NEMO-polyubiquitin
complex, A20 directly impairs phosphorylation of IKK by TAK1. Importantly, the catalytic
Cys 103 residue of A20 is dispensable for this mechanism of inhibition. Our results
therefore suggest a direct, non-catalytic mechanism of IKK inhibition by A20 and
demonstrate that polyubiquitin chains can induce specific binding among proteins to which
ubiquitin is not covalently attached.
RESULTS
Overexpressed A20 Impaired IKK Activation Without Reducing RIP1 Ubiquitination
As a tool to dissect the mechanism of IKK inhibition by A20, we stably overexpressed Flag-
A20 in a HEK293 cell line that expresses IL-1R. In this cell line, IKK activation by TNFα
was almost completely abolished, as evidenced by the lack of IκBα degradation and the
failure of immunoprecipitated IKK complex to phosphorylate IκBα (Figure 1A). To test
whether IKK inhibition in this cell line was caused by disruption of the TNFR complex, we
stimulated cells with GST-TNFα, then pulled down the TNFR complex using glutathione-
Sepharose and immunoblotted for TRADD and RIP1. Surprisingly, TRADD and RIP1,
including a high molecular weight smear of RIP1 indicative of ubiquitination, were enriched
on TNFR in A20-overexpressing cells compared to parental cells (Figure 1B). Notably, A20
was also recruited to this complex. We also immunoprecipitated NEMO from TNFα-treated
cells and compared the abundance of ubiquitinated RIP1 that interacted with NEMO in A20-
overexpressing vs. parental cells. Remarkably, NEMO co-immunoprecipitated more
ubiquitinated RIP1 from the A20-overexpressing cells, and A20 was also present in this
complex (Figure 1C). Thus, overexpressed A20 was recruited to the NEMO-RIP1 complex
and inhibited IKK activation, apparently without deubiquitinating RIP1, causing degradation
of RIP1, inhibiting ubiquitination of RIP1, or disrupting the interaction of NEMO with
polyubiquitinated RIP1. Although a previous study showed A20-dependent deubiquitination
and degradation of RIP1 (Wertz et al., 2004), perhaps this outcome was dependent on cell
types and other experimental conditions.
To determine if the DUB activity of A20 is important for IKK inhibition, we established
stable cell lines in which wild-type A20 (WT) and the catalytically inactive A20 (C103A)
were overexpressed to a similar extent. In this case, the construct used for A20 expression
contained an N-terminal tandem affinity purification (TAP) tag, consisting of Protein A;
TEV Protease cleavage site; then calmodulin binding peptide, as well as a C-terminal Flag
tag. Supporting the idea that IKK inhibition by A20 does not require deubiquitination, IκBα
degradation did not occur when either A20 WT or C103A was overexpressed (Figure 1D).
Notably, immunoblots for UBC13 and UBC5 showed no change in their abundance
regardless of A20 expression level, suggesting that the IKK inhibition observed in these
cells was not due to degradation of these E2 enzymes.
A20 Inhibits IKK Downstream of TRAF6 Through a Non-Catalytic Mechanism
To further dissect the mechanism of IKK inhibition by A20, we tested whether purified A20
protein could inhibit IKK activation by TRAF6 in a cell-free system (S100) (Deng et al.,
2000). We purified A20 WT and C103A from the cell lines described above, in which A20
has an N-terminal TAP tag and C-terminal Flag tag, by two-step affinity purification (IgG-
Sepharose followed by anti-Flag antibody Sepharose) (Figure 2A, left). Consistent with cell-
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based assays (Figure 1D), both A20 WT and C103A impaired IKK activation by TRAF6 in
the cell-free system (Figure 2A, right).
ZnF7-Dependent Polyubiquitin Binding is Important for IKK Inhibition
To elucidate this non-catalytic mechanism of IKK inhibition, we considered alternative
biochemical properties of A20. A recent study found that A20 ZnF4 can bind to K63
polyubiquitin chains, and that this binding is important for NF-κB inhibition (Bosanac et al.,
2010). Yet the potential contribution of other regions of A20 to polyubiquitin binding has
not been addressed. To assess polyubiquitin binding, we mixed partially purified Flag-A20
with K63 polyubiquitin chains synthesized by TRAF6 and UBC13/UEV1A in which some
of the ubiquitin has an HA tag, then performed Flag immunoprecipitation followed by HA
immunoblotting. A mutant lacking the ovarian tumor domain (ΔOTU), but not one lacking
the seven ZnF motifs (ΔZnF), bound to polyubiquitin chains as well as A20 WT (Figure 2B,
C). To identify specific ZnFs involved in polyubiquitin binding, mutants lacking one or
more ZnFs (ZnF 2–7, 3–7, 4–7, 5–7, 6–7, 1–6, 1–5, and 1–4) were tested. Interestingly, a
substantial binding defect was observed in a mutant lacking only ZnF7 (Figure 2D, lane 3).
ZnF4-7 and ZnF5-7, but not ZnF7 alone or ZnF1-5, were sufficient to bind polyUb,
indicating that multiple ZnFs contribute to polyUb binding and neither ZnF4 nor ZnF7 was
sufficient for this binding.
Co-crystallization of the ZnF motif of Rab5 guanine nucleotide exchange factor (RABEX-5)
with ubiquitin revealed ZnF residues that interact with ubiquitin, including Tyr 26 and Gly
27 (Lee et al., 2006; Mattera et al., 2006; Penengo et al., 2006). We mutated the
corresponding A20 ZnF7 residues Phe 770 and Gly 771, or the highly conserved Cys 779
and Cys 782, to Ala, and compared them to A20 WT or ΔZnF7. A20 ΔZnF7, C779A/
C782A, and F770A/G771A had an equally severe impairment in polyubiquitin binding
(Figure 2E). Importantly, each of these mutants was defective in IKK inhibition in S100
(Figure 2F), suggesting that ZnF7’s contribution to polyubiquitin binding is important for
IKK inhibition in vitro.
Retrovirus-mediated expression of A20 WT or C103A in A20-deficient MEFs (A20−/−)
limited IL-1β-induced IKK activation to a level similar to that observed in wild type
(A20+/+) MEFs (Figure 2G, lanes 1–16; Figure S1A). By contrast, A20 F770A/G771A
failed to inhibit IKK activation (Figure 2G, lanes 17–20). Similarly, for TNFα-induced IKK
activation, expression of A20 WT or C103A largely rescued A20 function in A20−/− MEFs,
while A20 F770A/G771A was defective (Figure S1B). Thus, in the first few minutes of
ligand detection in MEF cells, Cys 103 is dispensable for limiting inflammatory cytokine-
induced IKK activation, while ZnF7-dependent polyubiquitin binding is important.
To further test the roles of Cys 103 and polyUb binding for NF-κB downregulation in cells,
we established stable cell lines wherein A20 WT, C103A, F770A/G771A (ZnF7*), or
Y614A/F615A (ZnF4*) were expressed at similar levels in A20−/− MEFs (Figure 3A). The
Y614A/F615A mutation was previously shown to impair Ub binding and NF-κB
downregulation (Bosanac et al., 2010). We used RT-PCR to measure expression of two NF-
κB target genes, interleukin-6 (IL-6) and cyclooxygenase-2 (COX-2) before or after
stimulation of these cells for 3 hr with TNFα. Not surprisingly, A20−/− MEFs expressing
GFP as a control had much higher levels of IL-6 and COX-2 mRNA than A20+/+ MEFs
expressing GFP, and expression of A20 WT largely suppressed IL-6 and COX-2 expression
(Figure 3B). Expression of IL-6 and COX-2 in cells with A20 C103A was higher than what
was observed in cells with A20 WT, but substantially less than that in cells with GFP. This
suggests that downregulation of NF-κ B by A20 is partially dependent on Cys 103.
Importantly, IL-6 and COX-2 expression was significantly elevated in cells expressing
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either A20 ZnF7* or ZnF4*, confirming the key role of polyUb binding for suppressing NF-
κB activity.
Importantly, no change was seen in the abundance of RIP1, UBC13, or UBC5 over the
three-hour TNFα treatment regardless of whether A20 WT or mutants were expressed
(Figure 3C). Thus, over this time period, A20 did not appear to affect the overall stability of
these proteins. To see whether TNFα-induced RIP1 ubiquitination was affected by A20 in
these cell lines, we immunoprecipitated NEMO from untreated or TNFα-treated cells and
immunoblotted for RIP1. A20+/+ MEFs and A20−/− MEFs expressing A20 WT had
ubiquitinated RIP1 conjugates with molecular weights slightly lower than those in A20−/−
MEFs expressing GFP or A20 mutants (Figure 3D). This suggests that, in these cells, A20
WT is having some effect on RIP1 ubiquitination status. Nevertheless, A20 WT and C103A
each appeared to impair TNFα-induced IKK phosphorylation as compared to A20−/− cells
expressing GFP, whereas the ZnF7 and ZnF4 Ub-binding mutants did not (Figure 3D;
compare lanes 8, 11, 14 & 17). Therefore RIP1 ubiquitination status appears to be not
entirely predictive of IKK activation, i.e., A20 C103A impaired IKK activation even though
it did not reduce RIP1 ubiquitination (lanes 10–12).
Polyubiquitin Chains Induce NEMO-A20 Interaction
A20 was previously found to interact with NEMO in a yeast two-hybrid screen and when
both proteins were overexpressed in mammalian cells (Zhang et al., 2000). Given that A20
and NEMO are each recruited to polyubiquitin chains, we reasoned that their proximity
might promote interaction with one another. Indeed, endogenous NEMO and A20 co-
immunoprecipitated following IL-1β stimulation of HeLa cells with kinetics that correlated
with IKK activity (Figure 4A). Similarly, TNFα stimulation of HEK293 cells induced
interaction between NEMO and A20, concomitant with IKK activation (Figure S2A, lanes
1–4). This correlation suggested that IKK might promote NEMO-A20 interaction, which
could explain how phosphorylation of A20 by IKK promotes NF-κB suppression (Hutti et
al., 2007). However, to our surprise, the IKK inhibitor TPCA-1 enhanced TNFα-induced
NEMO-A20 interaction (Figure S2A, lanes 5–8), suggesting that the kinase activity of IKK
impairs NEMO-A20 interaction, while an alternative signal induces it. To identify this
signal, NEMO-A20 interaction was examined in HeLa S100. The combination of TRAF6
and TPCA-1, or an alternative IKK inhibitor BMS-345541, induced NEMO-A20 interaction
(Figures 4B and S2B). Addition of the deubiquitination enzyme vOTU (OTU domain from
Crimean Congo Hemorrhagic Fever Virus L1 protein (Frias-Staheli et al., 2007)) abolished
this interaction (Figure 4C, compare lanes 3 & 6). Depletion of UBC13 from S100 also
abolished NEMO-A20 interaction, which was rescued by adding back recombinant His6-
Ubc13 (Figure 4C, compare lanes 9 & 12). Thus, TRAF6/UBC13-synthesized polyubiquitin
chains induce NEMO-A20 interaction. In support of this notion, A20 WT, but not the
polyubiquitin-binding mutant F770A/G771A, co-immunoprecipitated with NEMO from
S100 in a TRAF6-dependent manner (Figure 4D). NEMO’s interaction with A20 was
selective, because under the same conditions it did not interact with the proteasomal subunit
S5A, which also bound to polyubiquitin chains (Figure S2C, right panel).
We next examined NEMO-A20 interaction in human osteosarcoma cells (U2OS) in which
ubiquitin is knocked down by tetracycline-inducible shRNA, and replaced with tetracycline
inducible RNAi-resistant WT or K63R Ub (Xu et al., 2009). IL-1β-induced interaction
between NEMO and A20 was reduced in cells expressing the K63R mutant compared to
cells expressing WT Ub (Figure 4E), indicating that K63 polyubiquitination provides a
signal for NEMO-A20 interaction in cells.
In further support of the role of polyubiquitin in promoting signal-dependent interaction
between A20 and NEMO in cells, we found that A20 WT, but not the ZnF7 or ZnF4 Ub-
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binding mutants, was co-immunoprecipitated with NEMO following TNFα stimulation of
MEF cells stably expressing the A20 proteins (Figure 4F).
Polyubiquitin Chains Directly and Non-Covalently Induce Binding of A20 to NEMO
To determine if polyubiquitin chains directly promote NEMO-A20 interaction, we incubated
highly purified K63 polyubiquitin chains, recombinant GST-NEMO, and A20, then
performed GST pull down analyses. These polyubiquitin chains had been synthesized by
recombinant E1, UBC13/UEV1A, and TRAF6, each of which was His6-tagged. The
polyubiquitin chains were subsequently separated from the ubiquitination enzymes by nickel
depletion and gel filtration (Figure S3A–C). NEMO and A20 did not detectably interact in
the absence of polyubiquitin chains, but robustly interacted in their presence (Figure 5A).
Importantly, A20 did not impair the interaction between NEMO and polyubiquitin chains,
even when A20’s molar concentration was roughly 6-fold greater than that of NEMO (lane
8). This result suggests that non-covalent binding to polyubiquitin chains directly induces
NEMO-A20 interaction. To confirm that the polyubiqutin chains inducing NEMO-A20
interaction were indeed “free,” or unanchored, we treated them with the deubiquitination
enzyme Isopeptidase T (IsoT), which is specific for unanchored polyubiquitin chains
(Reyes-Turcu et al., 2006). IsoT treatment destroyed the vast majority of polyubiquitin
chains, and abolished the NEMO-A20 interaction (Figure 5B), supporting the idea that
unanchored polyubiquitin chains can induce NEMO-A20 interaction. In contrast to long
polyubiquitin chains, tetraubiquitin (Ub4) of K63-, K48-, or linear linkage did not induce
NEMO-A20 interaction, nor did it affect NEMO-A20 interaction in the presence of long
polyubiquitin chains (Figure S3E–G). It should be noted that, under the experimental
conditions used here, NEMO bound to long polyubiquitin chains much more robustly than
to Ub4 (Figure S3F). Therefore, the inability of Ub4 to affect NEMO-A20 binding may
simply reflect the relatively low affinity between NEMO and short polyubiquitin chains.
In a yeast two-hybrid screen, it was found that A20’s interaction with NEMO required a
region of NEMO encompassing residues 95–218, which includes its first coiled coil domain
(Zhang et al., 2000). On the other hand, polyubiquitin chains bind to NEMO’s C-terminus,
which contains two ubiquitin binding domains in tandem (Ea et al., 2006; Laplantine et al.,
2009; Wu et al., 2006). This suggests that distinct regions of NEMO mediate interaction
with A20 and polyubiquitin chains. To test this idea, we purified a fragment of NEMO
lacking the first coiled coil domain but containing the ubiquitin-binding domains (251–419,
or NEMO ΔN). NEMO ΔN did not bind A20 even in the presence of polyubiquitin chains
(Figure 5C, lanes 7–9). In fact, A20 reduced the binding of NEMO ΔN to polyubiquitin
chains (lane 9), suggesting that A20 and NEMO ΔN compete for polyubiquitin binding,
whereas A20 and full-length NEMO cooperate to form a ternary complex in the presence of
polyubiquitin. The formation of this complex involves not only the binding of NEMO and
A20 to polyubiquitin chains, but also a domain within NEMO’s N-terminus, presumably
because this domain interacts directly with A20 (Figure 5D).
If this complex involves direct interaction between NEMO and A20, it is expected that other
polyubiquitin-binding proteins will not bind to NEMO under these conditions, assuming
they lack an interface for binding to NEMO. Indeed, interaction was not detected between
NEMO and recombinant TAB2 in the presence or absence of polyubiquitin chains; rather,
TAB2 at high concentration appeared to compete with NEMO for binding to polyubiquitin
chains (Figure S3D, lane 14). These results suggest that polyubiquitin chains can directly
and non-covalently induce specific binding between NEMO and A20 (see Discussion).
Skaug et al. Page 6













A20 Prevents IKK Phosphorylation by TAK1
The signal-induced recruitment of A20 to NEMO suggests that A20 might directly regulate
IKK. However, the activity of IKK complex immunoprecipitated from TNFα-stimulated
cells was unaffected by A20 in vitro (Figure 6A). In fact, removal of polyubiquitin chains
from NEMO-associated RIP1 by vOTU did not affect IKK activity, whereas
dephosphorylation by lambda phosphatase abolished it (Figure 6B). Thus, IKK
phosphorylation appears to be the primary determinant of its kinase activity.
We then tested whether A20 could prevent IKK phosphorylation, using an assay in which
IKK complex is activated by TAK1 in the presence of unanchored K63 polyubiquitin chains
(Xia et al., 2009). To uncouple the processes of TAK1 and IKK activation, TAK1 was first
activated by polyubiquitin chains, which were subsequently destroyed using vOTU, then the
TAK1 complex was affinity purified (Figure 6C). Phosphorylation of MKK6 by this
constitutively active TAK1 (TAK1-ca) was no longer subject to regulation by polyubiquitin
chains (Figure 6D, bottom). Interestingly, phosphorylation of IKK by TAK1-ca was
significantly enhanced by polyubiquitin chains (Figure 6D, top; compare lanes 5 & 6),
indicating that polyubiquitin chains are required not only for TAK1 activation, but also for
the phosphorylation of IKK by active TAK1. Remarkably, A20 had no effect on
phosphorylation of MKK6 by TAK1-ca, but impaired phosphorylation of IKK (Figure 6E,
top and middle), indicating that A20 can impair IKK phosphorylation without affecting
TAK1 activity per se. As a control, phosphorylation of IKK by the kinase MEKK1, which
does not require ubiquitin, was unaffected by A20 (Figure 6E, bottom). Importantly, A20
C103A impaired IKK phosphorylation as potently as A20 WT, whereas further deletion of
ZnF7 attenuated this inhibitory activity (Figure 6F). These results provide direct evidence
that A20 inhibits IKK by preventing the phosphorylation of IKK by TAK1.
We have previously shown that purified IKK complex could be activated by polyubiquitin
chains synthesized by TRAF6 and UBC5 through a mechanism involving the binding of
NEMO to polyUb, which in turn induces IKK autophosphorylation (Xia et al., 2009).
Interestingly, A20 blocked IKK autophosphorylation in a manner independent of Cys 103,
and this inhibition was impaired by deletion of A20’s 7th ZnF (Figure S4A, B). Importantly,
the A20:NEMO molar ratio required for IKK inhibition was roughly 1:1 (lanes 3–4). Yet,
even at an A20:NEMO ratio of roughly 5:1, A20 did not impair the binding of NEMO to
polyUb (Figure S4C). Therefore, formation of the polyubiquitin-NEMO-A20 complex is
sufficient to impair IKK activation.
Notably, we found that A20 could also impair TAK1 activation by K63-linked polyubiquitin
chains, as measured by TAK1 autophosphorylation and phosphorylation of MKK6 (Figure
S4D). As was the case with IKK, impairment of TAK1 activation did not require
deubiquitination, but was attenuated when ZnF7 was mutated. These results suggest that
A20 can also limit the activation of TAK1 in a manner dependent on polyubiquitin binding,
which may promote the interaction between A20 and TAB2.
Taken together, our results suggest that A20 can inhibit autophosphorylation of TAK1,
phosphorylation of IKKβ by TAK1, as well as autophosphorylation of IKK, all of which
involve polyubiquitin binding to TAB2 or NEMO. Through its ability to bind
simultaneously to polyubiquitin chains and NEMO, and possibly TAB2, A20 limits the
activation of IKK and TAK1.
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Direct, Non-Catalytic Impairment of IKK Activation by A20
Our results suggest a mechanism by which A20 inhibits IKK without deubiquitination or
impairment of ubiquitination enzymes. We propose that, within the first few minutes of
ligand detection, A20 forms a complex with polyubiquitin chains and NEMO and non-
catalytically limits the extent of IKK activation by TAK1 (Figure 7). Indeed, we present
multiple lines of evidence that A20 inhibits IKK through a non-catalytic mechanism. First,
when overexpressed, A20 inhibits TNFα-induced IKK activation without impairing
ubiquitination of RIP1 or the interaction between ubiquitinated RIP1 and NEMO (Fig. 1).
Second, in cell-free systems that recapitulate the IL-1R signaling pathway, the C103A
mutant of A20 is as potent as A20 WT in inhibition of IKK (Fig. 2A; Fig. 6F). Finally, A20
C103A inhibits IKK activation when expressed in A20−/− MEFs (Fig. 2G; Fig. S1). Our
measurements of NF-κB target gene expression suggest that the majority of NF-κB
downregulation by A20 does not require the catalytic Cys 103 residue, although the C103A
mutant was partially defective (Figure 3B). Of course, elucidation of the specific role of Cys
103 in mammalian physiology will likely require generation of a knockin mouse harboring
mutation of this residue.
Our results suggest that multiple A20 ZnFs contribute to polyubiquitin binding, including a
prominent contribution by ZnF7 (Figure 2C). Consistent with a key role for ZnF7, mutations
in this motif that impair polyubiquitin binding reduce A20’s ability to inhibit IKK in vitro
and in reconstituted A20−/− MEFs (Figures 2E–G, S1), and to suppress NF-κB target gene
expression (Figure 3B). It is noteworthy that among the mutations in the A20 gene
(TNFAIP3) identified in B-cell lymphoma patients, the majority results in premature stop
codons or frameshifts that preclude synthesis of some or all of the ZnFs (Compagno et al.,
2009; Kato et al., 2009; Schmitz et al., 2009). Although their locations vary widely, almost
all of these mutations occur prior to ZnF7. Our results suggest that each of these mutations
causes a polyubiquitin-binding defect, which is sufficient to cause IKK dysregulation,
although other biochemical properties of A20 affected by the mutations should also be
considered.
Our results indicate that an outcome of polyubiquitin binding by A20 is its recruitment to
NEMO. Binding between A20 and NEMO was initially reported more than a decade ago
(Zhang et al., 2000), but the relevance of this interaction, and its potential regulation, have
not been clearly defined. We found that A20 is recruited to NEMO by polyubiquitin chains,
and when bound, can impair IKK activation. Thus, NEMO can receive both positive and
negative IKK-regulatory signals. Remarkably, K63 polyubiquitin chains not only serve as a
signal for the activation of TAK1 and IKK, but also as a signal for the recruitment of A20 to
NEMO to limit IKK activation, suggesting a ‘built-in brake’ mechanism that tightly controls
NF-κB activation.
Consistent with what was reported by Wertz et al. (2004) and Bosanac et al. (2010), we have
found that A20’s C-terminal ZnF region can catalyze polyUb synthesis in the presence of E1
and UBC5, and this activity was impaired by mutation of ZnF4 (Figure S5, lanes 2 and 4).
Interestingly, this activity was also impaired by mutation of ZnF7 (F770A/G771A) (lanes 2
and 3). This result suggests an unexpected role for ZnF7 Ub binding in A20’s E3 ligase
activity. Because these mutations also impair A20’s recruitment to NEMO following TNFα
detection (Figure 4F), it is difficult to delineate the cause of impaired NF-κB
downregulation by the A20 ZnF7 and ZnF4 mutants in vivo (Figure 3B). Although we
cannot rule out a role for A20 E3 ligase activity in downregulation of NF-κB in vivo, we did
not detect an A20-dependent decrease in the stability of RIP1, UBC13, or UBC5 in the time
periods we examined (Figure 3C). Given the ability of A20 to directly impair IKK
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phosphorylation when bound to NEMO in vitro, as well as the rapid recruitment of A20 to
NEMO that correlates with IKK inhibition in cells, we think it is likely that direct, non-
catalytic impairment of IKK activation plays an important role.
A previous study showed that A20 is recruited to E2–E3 ubiquitination enzymes such as
UBC13 and TRAF6, leading to disruption of the E2–E3 interaction (Shembade et al., 2010).
This recruitment, which is dependent on A20’s Cys 103 residue, appears to occur after IKK
activity has declined from its peak, and may therefore serve to further reduce IKK activity
towards its basal level and to desensitize the pathway to additional upstream stimulation.
In cells, recruitment of A20 to NEMO, TRAFs and RIP1 is facilitated by a multitude of
A20-interacting proteins, including ABINs, TAX1BP1, ITCH, and RNF11 (Iha et al., 2008;
Mauro et al., 2006; Shembade et al., 2007; Shembade et al., 2008; Shembade et al., 2009).
We found evidence that IKK activity can limit the extent of A20 recruitment to NEMO. It
seems plausible that IKK cooperates with the A20-regulatory proteins to regulate the timing
and magnitude of A20 recruitment. In principle, it is logical to limit recruitment of A20,
because if recruited in excess, A20 does not allow IKK activation (Figure 1A). Thus, IKK
may enable its own activation by imposing a limit on the extent of A20 recruitment, and the
function of the A20-interacting proteins might be to “release” some A20 from this limitation
to allow its interaction with polyubiquitin chains, NEMO, and potentially other upstream
factors. Further studies are required to elucidate the mechanism(s) by which IKK and the
A20-interacting proteins regulate the function of A20. In any case, it appears that ubiquitin-
mediated recruitment of A20 to NEMO is sufficient to impair IKK activation through a non-
catalytic mechanism.
A Basis For Specificity In Ubiquitin-Mediated Signal Transduction
We have identified a complex between K63 polyubiquitin chains, A20, and NEMO.
Remarkably, the ubiquitin binding domain of NEMO is insufficient for complex formation.
Rather, the N-terminus of NEMO is required, presumably because it makes direct contact
with A20. A ternary complex of a similar nature was previously described (Kang et al.,
2007). In this case, one UIM domain of the proteasome subunit S5A binds to the ubiquitin-
like domain of hHR23a, while the other UIM domain of S5A and the UBA domain of
hHR23a bind to a K48-linked polyubiquitin chain. This interaction may facilitate delivery of
K48 polyubiquitin chains into the proteasome. Our results suggest that this type of complex
can also form in the context of signal transduction, leading to specific interaction among
ubiquitin binding proteins. Importantly, this interaction can be achieved with polyubiquitin
chains that are not attached to a target protein, such as those synthesized by TRAF6 and
UBC13/UEV1A. Thus, unanchored polyubiquitin chains are sufficient to induce specific
protein-protein interaction. This mode of interaction may help to account for the specific
signaling outputs achieved by polyubiquitin chains in diverse cellular pathways.
EXPERIMENTAL PROCEDURES
Stimulation of Cells and Analyses by Immunoblotting, Immunoprecipitation, and Kinase
Assays
HEK293 cells, HeLa cells, U2OS cells, or MEFs were treated with IL-1β (30 ng/ml) or
GST-TNFα (1 μg/ml). Cells were lysed in Buffer A (20 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 20 mM β-glycerolphosphate, 1 mM DTT, 0.5% NP-40, and Complete protease
inhibitor cocktail [Roche]). Cell lysates were centrifuged at 20,000 × g for 10–15 min, and
supernatant was used for immunblotting or immunoprecipitation according to standard
protocols.
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For IKK activity assays, following immunoprecipitation of NEMO and several washes in
Buffer A, immunoprecipitate was washed with Buffer B (20 mM Tris-HCl [pH 7.5], 1 mM
DTT, 20 mM β-glycerolphosphate, 0.05% NP-40). The immunoprecipitate was incubated
with GST-IκBα N-terminus (0.1 mg/ml), 10 μM ATP, and γ-32P-ATP at 30° for 30 min.
Cell-Free Assays of IKK Activity
HeLa S100 was prepared according to standard protocols. S100 was mixed with 5X Buffer
C (100 mM Tris-HCl [pH 7.5], 2.5 mM DTT, 100 mM β-glycerophosphate, g of 12.5 mM
ATP, and 25 mM MgCl2) for a final concentration of 1X buffer C and 1.2 μg of total protein
per 1 μl. Flag-purified A20 was added as indicated, then His6-TRAF6 was added to ~100
nM final. After 30 min at 30°, reaction was analyzed by IκBα immunoblot.
For assays with purified TAK1 and IKK complexes, IKK complex was used at ~5 nM,
TAK1 complex at ~1 nM, MKK6 (K82A) at ~1 μM, and two-step affinity-purified A20 at
~3–100 nM. Synthesis and purification of polyubiquitin chains, as well as purification of
TAK1 and IKK complexes, were described previously (Xia et al., 2009). Components were
mixed with Buffer C. After 30 min at 30°, reaction was analyzed by immunoblotting as
indicated.
A20 Polyubiquitin Binding Assays
Constructs encoding N-terminally Flag-tagged A20, or mutants thereof, were transfected
into HEK293 cells by calcium phosphate precipitation. Cells were lysed in Buffer D, and
20,000 × g supernatant was incubated for 4–6 hr with anti-FLAG (M2) agarose. Beads were
washed with Buffer D (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM DTT, 0.5%
NP-40), then with Buffer E (20 mM Tris-HCl [pH 7.5], 50 mM NaCl, 1 mM DTT, 0.05%
NP-40, 5% glycerol). Protein was eluted with 0.2 mg/ml Flag peptide. This partially purified
A20 was mixed with polyubiquitin chains synthesized by E1, UBC13/UEV1A, and TRAF6,
in which some of the ubiquitin had an HA tag (Boston Biochem), in Buffer F (20 mM Tris-
HCl [pH 7.5], 100 mM NaCl, 0.5 mM DTT, 0.2% NP-40, 5% glycerol, 0.1 mg/ml BSA) on
ice for 15 min. 10% of reaction was analyzed by immunoblotting for HA. Remaining
reaction was diluted 1:10 in Buffer F, then mixed with M2 agarose. Beads were rinsed with
Buffer G (Buffer F without BSA), then with Buffer E. A20 was eluted with 0.2 mg/ml Flag
peptide. Eluate was analyzed by immunoblotting for HA and Flag.
RT-PCR measurements of NF-κB target gene expression
RNA was extracted using Trizol, then chloroform using standard protocols. The iScript
cDNA synthesis kit (BioRad) was used to create cDNA from 150 ng of RNA. Quantitative
real time PCR was performed using Sybr® Green on a BioRad iCycler iQ™5 with the
following primers: rp119 (AAATCGCCAATGCCAACTC;
TCTTCCCTATGCCCATATGC); IL-6 (TCCATCCAGTTGCCTTCTTG;
GGTCTGTTGGGAGTGGTATC); COX-2 (TCC TCA CAT CCC TGA GAA CC; AAG
TGG TAA CCG CTC AGG TG). rp119 values were used as a standard for IL-6 and COX-2
values. Data were normalized to unstimulated WT MEFs.
Direct Binding Between NEMO, Polyubiquitin Chains, and A20
GST or GST-NEMO (~20 nM), two-step affinity-purified A20 (~10–120 nM) and purified
K63 polyubiquitin chains (~25 nM assuming average molecular weight of 400 kDa) were
mixed on ice for 15 min in Buffer F. 10% of the reaction was analyzed by immunoblotting
as indicated. Remaining reaction was diluted 10-fold in Buffer F. Glutathione Sepharose 4B
(GE Healthcare) was added and samples were rotated end-over-end at 4° for 1 hr. Beads
were washed several times in Buffer G, then analyzed by immunoblotting as indicated.
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Figure 1. A20 inhibits TNFα-induced IKK activation without antagonizing RIP1 ubiquitination
(A) HEK293 cells stably overexpressing A20 and the parental (WT) HEK293 cells were
stimulated with TNFα for the indicated time, then IKK complex was immunoprecipitated
with a NEMO antibody for kinase assay using GST-IκBα N-terminus and γ-32P-ATP as
substrates. Immunoprecipitates and cell lysates were immunoblotted with the indicated
antibodies. N.S.: non-specific. (B) TNF receptor complexes were pulled down using
glutathione Sepharose following stimulation of cells with GST-TNFα, and the proteins in
the complexes were detected by immunoblotting with the indicated antibodies. (C) Similar
to (B), except that a NEMO antibody was used for immunoprecipitation. (D) Parental
HEK293 cells (WT) or HEK293 cells stably expressing A20 WT or A20 C103A with N-
terminal TAP tag and C-terminal Flag tag were treated with TNFα for the indicated
timepoints. Cell lysates were used for immunoblotting with the indicated antibodies.
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Figure 2. Cys 103 is dispensable, while ZnF7-dependent polyubiquitin binding is important for
IKK inhibition by A20
(A) Left, silver stain of two-step affinity-purified A20. HSP70, 70kDa heat shock protein.
Right, different amounts of purified A20 (WT and C103A) were incubated with HeLa S100,
followed by addition of TRAF6 and ATP and further incubation for 1 hr. IKK activation in
S100 was measured by immunoblotting for IκBα. (B) Domain architecture of A20, including
relative locations of point mutations. OTU: ovarian tumor. ZnF: zinc finger. (C–E) Flag-
A20 mutants were expressed in HEK293 cells and affinity purified. After incubation with
HA-tagged polyubiquitin chains, A20 proteins were immunoprecipitated with a Flag
antibody and ubiquitin chains were immunoblotted with an HA antibody. (F) IKK activation
in S100 was measured as in (A). CC(AA): C779A/C782A. FG(AA): F770A/G771A. (G)
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MEF cells were infected with retrovirus expressing either GST or Flag-A20 WT, C103A, or
F770A/G771A. The cells were stimulated with IL-1β, and then IKK activity was measured
as in Figure 1A. Fold activation indicates activity normalized to the activity of unstimulated
WT (A20+/+) cells (lane 1).
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Figure 3. The roles of A20’s catalytic Cys 103 residue and ubiquitin binding in downregulation
of NF-κB activity
(A) Lysates from cells stably expressing A20 or GFP as a control were examined for A20
expression by immunoblotting. (B) Cells were untreated or treated with TNFα for 3 hr. RNA
was extracted, and RT-PCR was performed to measure the relative expression of IL-6 or
COX-2 as described in Experimental Procedures. Error bars indicate the standard error of
the mean (SEM) among triplicates for each sample. Each graph is representative of three
independent experiments. (C & D) Cells were treated for the indicated times with TNFα.
Cell lysates were immunoblotted with the indicated antibodies; or immunoblotting was
performed following immunoprecipitation with a NEMO antibody (D).
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Figure 4. Polyubiquitin chains induce NEMO-A20 interaction
(A) HeLa cells were stimulated with IL-1β for the indicated time, then immunoprecipitation
was performed with a NEMO antibody. Immunoprecipitate was used to measure IKK
activity as in Figure 1A, or for immunoblotting with an A20 antibody. (B) S100 was
incubated with ATP, −/+ TRAF6, −/+ the IKK inhibitor TPCA-1 (10 μM), for 1 hr. A
NEMO antibody was used for immunoprecipitation. Proteins in the S100 and
immunoprecipitate were detected by immunoblotting with the indicated antibodies. (C) As
in (B), following depletion of UBC13 and/or addition of vOTU or (D) A20 WT or F770A/
G771A was added to S100. Experiment was His6-UBC13. performed as in (B) but without
TPCA-1. (E) shUb-Ub (WT) or shUb-Ub (K63R) cells were untreated or treated with 1 μg/
ml tetracycline for 4 days. Cells were then treated with TPCA-1 (20 μM) for 3 hr to enhance
NEMO-A20 association. Cells were stimulated with IL-1β for the indicated times, then a
NEMO antibody was used for immunoprecipitation. Proteins in the S100 and
immunoprecipitate were detected by immunoblotting with the indicated antibodies. (F) MEF
stable cell lines were treated for the indicated times with TNFα. Cell lysates were used for
immunoprecipitation with a NEMO antibody. Cell lysate and immunoprecipitate were
immunoblotted with the indicated antibodies.
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Figure 5. Polyubiquitin chains directly and non-covalently induce specific binding between
NEMO and A20
(A) GST or GST-NEMO was incubated with affinity-purified A20 in the presence or
absence of K63 polyubiquitin chains. After 15 min, 10% of input was withdrawn, and the
remaining mixture was incubated with Glutathione Sepharose. Input and glutathione pull-
down were immunoblotted using the indicated antibodies. (B) as in (A) except that, in lanes
6 & 7, polyUb was treated with isopeptidease T (IsoT). (C) As in (A), but including GST-
NEMO ΔN. (D) Model of the polyubiquitin-NEMO-A20 complex. NT: N-terminus. NUB:
NEMO ubiquitin binding. ZnF: zinc finger. Ub: ubiquitin.
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Figure 6. A20 inhibits IKK phosphorylation by TAK1 through a direct, non-catalytic mechanism
(A) HEK293 cells were untreated or treated with TNFα for 10 min, and a NEMO antibody
was used for immunoprecipitation. Immunoprecipitate was incubated with affinity-purified
A20, then washed and incubated with γ–32P-ATP and GST-IκBα N-terminus or
immunoblotted with the indicated antibodies. (B) as in (A), but NEMO immunoprecipitate
was treated with vOTU or lambda phosphatase. Immunoprecipitate was immunoblotted for
RIP1, p-IKK, or IKKβ. Aliquots of the immunoprecipitates were also assayed for IKK
activity by measuring IκBα phosphorylation. (C) Method to generate constitutively active
TAK1 (TAK1-ca). (D) TAK1 or TAK1-ca was incubated with IKK complex (top) or His6-
MKK6 (K82A) (bottom), −/+ polyubiquitin chains and ATP. Samples were immunoblotted
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for p-IKK or p-MKK6. (E) Top and middle: as in (D), except that A20 was included in the
reactions. Bottom: MEKK1 was used to activate IKK. (F) as in (D) top, except that the
reactions included A20 WT, C103A, or C103A/ΔZnF7.
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Figure 7. Model of the non-catalytic mechanism by which A20 limits IKK activation
Binding of IL-1β to IL-1R activates the E3 ligase TRAF6, which works with UBC13 to
synthesize K63-linked polyubiquitin chains. The TAK1 and IKK complexes are recruited
through ubiquitin binding domains on TAB2 and NEMO, respectively, allowing IKK
phosphorylation by TAK1. A20 is recruited to NEMO through bipartite binding to
polyubiquitin chains and an N-terminal region of NEMO. Formation of this complex blocks
IKK phosphorylation by TAK1, thereby inhibiting IKK.
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